Patents Represented by Attorney, Agent or Law Firm P. H. Ginsburg
  • Patent number: 6809094
    Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant &agr;7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant &agr;7 nicotinic receptor agonist.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: October 26, 2004
    Assignee: Pfizer Inc
    Inventors: Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
  • Patent number: 6794388
    Abstract: The present invention is directed to the succinate salts of 5,7,13-triazatetracyclo[9.3.1.02,10.04,8]-pentadeca-2(10),3,5,8-tetraene and pharmaceutical compositions thereof. The invention is also directed to a process for preparation of the succinate salts.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: September 21, 2004
    Assignee: Pfizer Inc.
    Inventors: George J. Quallich, Lewin T. Wint
  • Patent number: 6787549
    Abstract: The present invention is directed to the citrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene: and pharmaceutical compositions thereof. The present invention is also directed to the various forms of the citrate salt, particularly its hydrate and its anhydrous/nearly anhydrous polymorph. The invention is also directed to processes for preparation of these citrate salt forms.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: September 7, 2004
    Assignee: Pfizer Inc.
    Inventors: Phillip J. Johnson, Peter R. Rose, Glenn R. Williams, Lewin T. Wint
  • Patent number: 6727283
    Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
    Type: Grant
    Filed: October 11, 1999
    Date of Patent: April 27, 2004
    Assignee: Pfizer Inc.
    Inventors: Nancy J. Harper, Gautam R. Ranade, Willard M. Welch
  • Patent number: 6716875
    Abstract: This invention relates to compositions and methods for achieving a therapeutic effect such as lowering blood pressure and treating congestive heart failure in a mammal. More specifically, this invention relates to synergistic compositions comprising amounts of at least two therapeutic agents selected from the group consisting of a renin inhibitor, an angiotensin I converting enzyme inhibitor and an angiotensin II antagonist, which inhibitors and antagonists are present in amounts sufficient to cause synergistic therapeutic effects such as lowering blood pressure and treating congestive heart failure in a mammal.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 6, 2004
    Assignee: Pfizer Inc.
    Inventor: Anthony Andrea Fossa
  • Patent number: 6706702
    Abstract: The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: March 16, 2004
    Assignee: Pfizer Inc.
    Inventor: Jotham Wadsworth Coe
  • Patent number: 6677378
    Abstract: The present invention relates to compounds of the formula wherein R1 through R4, X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: January 13, 2004
    Assignee: Pfizer Inc.
    Inventors: Harry R. Howard, Jr., Christopher J. Schmidt, Thomas F. Seeger, Mark L. Elliott
  • Patent number: 6670476
    Abstract: The invention provides a process for the optical resolution of a racemic mixture, or an optically enriched mixture, of trans-7-(hydroxymethyl)octa-hydro-2H-pyrido-1,2a)pyrazine, a key intermediate for preparing pharmacologically active 2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives useful in the treatment of disorders of the dopamine system. The process of the invention involves use of D-(−) or L-(+)naproxen as a resolving agent.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: December 30, 2003
    Assignee: Pfizer Inc.
    Inventor: Arthur E. Harms
  • Patent number: 6664258
    Abstract: This invention relates to novel, pharmaceutically active compounds of formula (I) wherein a, b and R1 through R6 are as defined in the specification These compounds exhibit central dopaminergic activity and are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: December 16, 2003
    Assignee: Pfizer Inc
    Inventors: Anton F. J. Fliri, Todd W. Butler
  • Patent number: 6660999
    Abstract: A method and device for mass spectrometry analysis, wherein a mass spectrometer is adapted for use with helium droplets, as an ionization site medium, with a proton being initially captured by a large helium droplet (˜10,000 helium atoms) and then cooled evaporatively to 0.4 Kelvin. The protonated helium droplet then picks up a neutral molecule of interest and the neutral molecule is protonated inside of the droplet with the liquid helium droplet acting as a heat bath to provide rapid cooling of the newly formed protonated molecule. As a result, there is essentially no energy available, at 0.4 Kelvin, for the protonated molecule to fragment. Remaining liquid helium is removed and the stably maintained protonated molecule is detected by a mass spectrometer. Since the molecules do not fragment when protonated (ionized), each compound in a mixture analyses gives one mass and the number of ions of a particular mass detected is directly proportional to the molar percentage of that mass in the sample.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: December 9, 2003
    Assignee: Pfizer Inc.
    Inventor: Raymond J. Bemish
  • Patent number: 6632831
    Abstract: The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: October 14, 2003
    Assignee: Pfizer Inc.
    Inventors: Sheryl Jeanne Hays, Lain-Yen Hu, Huangshu Lei, Jeffrey David Scholten, David Juergen Wustrow
  • Patent number: 6627643
    Abstract: This invention relates to methods of preparing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I′ and methods of preparing pharmaceutical compositions comprising such NHE-1 inhibitors.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: September 30, 2003
    Assignee: Pfizer Inc.
    Inventors: Frank R. Busch, Gregory J. Withbroe
  • Patent number: 6627627
    Abstract: The present invention relates to compounds of the formula wherein R1, R2, R3, X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: September 30, 2003
    Assignee: Pfizer Inc.
    Inventor: Harry Ralph Howard
  • Patent number: 6610707
    Abstract: Compounds of the formula: wherein R1, Y, W, A and R2 are as defined above are inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases and nerve damage.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: David John Bull, Robert John Maguire, Michael John Palmer, Martin James Wythes
  • Patent number: 6608195
    Abstract: The present invention relates to a novel process for the preparation of a compound of formula I: wherein R1 is defined herein and compounds of formula II: wherein R1 and R2 are defined herein. Said compound of formula I is useful in the treatment of various central nervous system disorders including depression.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: August 19, 2003
    Assignee: Pfizer Inc.
    Inventors: Joseph P. Rainville, Terry G. Sinay, Stanley W. Walinsky
  • Patent number: 6605610
    Abstract: Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; and methods of using such compounds in the treatment of neurological and psychological disorders.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: August 12, 2003
    Assignee: Pfizer Inc
    Inventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
  • Patent number: 6602874
    Abstract: A compound of the formula wherein X, Y, Z, R2 and R3 are as defined above, useful in treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: August 5, 2003
    Assignee: Pfizer Inc.
    Inventor: Harry R. Howard
  • Patent number: 6596741
    Abstract: The present invention relates to compounds of formula I: and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: July 22, 2003
    Assignee: Pfizer Inc
    Inventors: Harry R. Howard, Mavis D. Adam
  • Patent number: 6579898
    Abstract: A composition comprising eletriptan and a p-glycoprotein (p-gp) inhibitor useful for the treatment of migraine. The bioavailability of eletriptan can be increased by co-administering eletriptan with a p-gp inhibitor. The eletriptan and p-gp inhibitor can be administered together in a composition or as separate components. If administered separately, they can be embodied as a kit. Also provided is a method of treating migraine using said composition or sequential administration of components.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: June 17, 2003
    Assignee: Pfizer Inc.
    Inventor: Michael John Humphrey
  • Patent number: 6562813
    Abstract: The present invention relates to compounds of the formula wherein R1, R2, R3, X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.
    Type: Grant
    Filed: March 6, 2002
    Date of Patent: May 13, 2003
    Assignee: Pfizer Inc.
    Inventor: Harry Ralph Howard